Eli Lilly Drops 4.1% Despite Positive Alzheimer's Trial Results

On July 29, 2025, Eli Lilly's stock experienced a significant drop of 4.1% in pre-market trading, reflecting a notable decline in investor sentiment.

Analysts have expressed mixed views on Eli Lilly's stock, with some predicting a potential rise of 7% due to positive interim results from an early Alzheimer's trial. BMO Capital has highlighted the potential for Eli Lilly's stock to gain momentum based on these results. Additionally, Guggenheim reiterated its Buy rating on the stock, citing strong sales projections for Mounjaro and Zepbound.

Eli Lilly's recent developments include the FDA approval of Kisunla for a safer Alzheimer's dosing schedule and the completion of the acquisition of Verve Therapeutics. These moves are aimed at advancing one-time treatments for individuals at high cardiovascular risk. Furthermore, the company's Jaypirca (pirtobrutinib) met its primary endpoint in a Phase 3 trial, demonstrating its efficacy in treating CLL/SLL.

Despite these positive developments, Eli Lilly's stock has faced challenges, including concerns over potential tariffs and the impact on the healthcare sector. Analysts have also noted the company's need for breakthroughs in new areas to sustain growth. However, Eli Lilly's strong pipeline and strategic acquisitions position it well for future growth.